Two-Year Follow-Up of Latanoprost 0.005% Monotherapy After Changing from Previous Glaucoma Therapies

200424 citationsJournal Article

Authors

Andreas Bayer · Research Network (United States)

Winfried Weiler · Sana Klinikum Offenbach

Ulrich Oeverhaus · Rietberg Museum

Frank-Eugen Skrotzki · Yara (Germany)

William C. Stewart · University of South Carolina

Xplore Observation Group

Abstract

The mean IOP was maintained at an acceptable level throughout the 2-year follow-up period on latanoprost. Latanoprost generally provides further reduction of IOP when switched from previous mono- and adjunctive therapies, with a low rate of side effects and discontinuations.

Topics & Keywords

Glaucoma and retinal disorders Ophthalmology and Eye Disorders Ocular Surface and Contact Lens

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Ocular Pharmacology and Therapeutics

Volume 20, Issue 6, pp. 470-478

DOI: 10.1089/jop.2004.20.470

Field-Weighted Citation Impact: 1.63